A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab

被引：4

作者：

Ito, Keima ^{[1
]}

Oguri, Tetsuya ^{[1
,2
,3
]}

Takeda, Norihisa ^{[1
]}

Fukumitsu, Kensuke ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Tajiri, Tomoko ^{[1
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
,2
,3
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Educ, Nagoya, Aichi, Japan

[3] Nagoya City Univ, Grad Sch Med Sci, Res Ctr Community Med, Nagoya, Aichi, Japan

来源：

RESPIRATORY MEDICINE CASE REPORTS | 2020年 / 29卷

关键词：

Lung cancer; Nivolumab; Immune checkpoint inhibitors; PD-L1; IPILIMUMAB; PEMBROLIZUMAB; RETREATMENT; MELANOMA; SAFETY;

D O I：

10.1016/j.rmcr.2019.100979

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

A 76-year-old man was admitted to our hospital with cough and dyspnea. He was diagnosed with advanced lung cancer. Nivolumab was given as second-line treatment, cytotoxic chemotherapy was given as third-line treatment, and nivolumab re-challenge was given as fourth-line treatment. Thereafter, 41 chemotherapy courses were administered over 2 years. Currently, he is being followed with no recurrence at least 10 months after treatment. Thus, the case of a patient with advanced lung cancer who was previously unsuccessfully treated with nivolumab and then demonstrated a long-term clinical response to a re-challenge with nivolumab after cytotoxic chemotherapy and radiation therapy is presented.

引用

页数：3

共 12 条

[1] Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases [J].

Fujita, Kohei ;

Uchida, Naohiro ;

Kanai, Osamu ;

Okamura, Misato ;

Nakatani, Koichi ;

Mio, Tadashi .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) :1105-1109

[2] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[3] Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies [J].

Lebbe, C. ;

Weber, J. S. ;

Maio, M. ;

Neyns, B. ;

Harmankaya, K. ;

Hamid, O. ;

O'Day, S. J. ;

Konto, C. ;

Cykowski, L. ;

McHenry, M. B. ;

Wolchok, J. D. .

ANNALS OF ONCOLOGY, 2014, 25 (11) :2277-2284

[4]

Niki Maiko, 2018, Oncotarget, V9, P32298, DOI 10.18632/oncotarget.25949

[5] Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab [J].

Nomura, Motoo ;

Otsuka, Atsushi ;

Kondo, Tomohiro ;

Nagai, Hiroki ;

Nonomura, Yumi ;

Kaku, Yo ;

Matsumoto, Shigemi ;

Muto, Manabu .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) :999-1004

[6] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma [J].

Pollack, M. H. ;

Betof, A. ;

Dearden, H. ;

Rapazzo, K. ;

Valentine, I. ;

Brohl, A. S. ;

Ancell, K. K. ;

Long, G. V. ;

Menzies, A. M. ;

Eroglu, Z. ;

Johnson, D. B. ;

Shoushtari, A. N. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :250-255

[7] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma [J].

Postow, Michael A. ;

Chesney, Jason ;

Pavlick, Anna C. ;

Robert, Caroline ;

Grossmann, Kenneth ;

McDermott, David ;

Linette, Gerald P. ;

Meyer, Nicolas ;

Giguere, Jeffrey K. ;

Agarwala, Sanjiv S. ;

Shaheen, Montaser ;

Ernstoff, Marc S. ;

Minor, David ;

Salama, April K. ;

Taylor, Matthew ;

Ott, Patrick A. ;

Rollin, Linda M. ;

Horak, Christine ;

Gagnier, Paul ;

Wolchok, Jedd D. ;

Hodi, F. Stephen .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2006-2017

[8] Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Vandormael, Kristel ;

Riccio, Antonio ;

Yang, Jing ;

Pietanza, M. Catherine ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) :537-+

[9] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[10] Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [J].

Shaverdian, Narek ;

Lisberg, Aaron E. ;

Bornazyan, Krikor ;

Veruttipong, Darlene ;

Goldman, Jonathan W. ;

Formenti, Silvia C. ;

Garon, Edward B. ;

Lee, Percy .

LANCET ONCOLOGY, 2017, 18 (07) :895-903

← 1 2 →